NELFCD
Basic information
Region (hg38): 20:58981208-58995133
Previous symbols: [ "TH1L" ]
Links
Phenotypes
GenCC
Source:
ClinVar
This is a list of variants' phenotypes submitted to
Variants pathogenicity by type
Statistics on ClinVar variants can assist in determining whether a specific variant type in the NELFCD gene is commonly pathogenic or not.
In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.
Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.
Variant type | Pathogenic | Likely pathogenic | VUS | Likely benign | Benign | Sum |
---|---|---|---|---|---|---|
synonymous | 0 | |||||
missense | 21 | 21 | ||||
nonsense | 0 | |||||
start loss | 0 | |||||
frameshift | 0 | |||||
inframe indel | 0 | |||||
splice donor/acceptor (+/-2bp) | 0 | |||||
splice region | 0 | |||||
non coding | 1 | |||||
Total | 0 | 0 | 21 | 0 | 1 |
Variants in NELFCD
This is a list of pathogenic ClinVar variants found in the NELFCD region.
You can filter this list by clicking the number of variants in the Variants pathogenicity by type table.
Position | Type | Phenotype | Significance | ClinVar |
---|---|---|---|---|
20-58981287-C-T | not specified | Uncertain significance (Feb 02, 2024) | ||
20-58981290-G-A | not specified | Uncertain significance (Jul 20, 2021) | ||
20-58981301-G-C | not specified | Uncertain significance (Jun 13, 2023) | ||
20-58981307-A-G | not specified | Uncertain significance (Feb 01, 2023) | ||
20-58981319-G-A | not specified | Uncertain significance (Sep 29, 2022) | ||
20-58981359-A-G | not specified | Uncertain significance (Mar 07, 2023) | ||
20-58986131-G-T | not specified | Uncertain significance (Feb 03, 2022) | ||
20-58987804-C-G | not specified | Uncertain significance (Apr 07, 2022) | ||
20-58988969-A-G | not specified | Uncertain significance (Apr 23, 2024) | ||
20-58989901-C-T | not specified | Uncertain significance (Dec 22, 2023) | ||
20-58989904-T-C | not specified | Uncertain significance (Apr 06, 2024) | ||
20-58989912-G-A | not specified | Uncertain significance (Jan 26, 2022) | ||
20-58990918-A-G | not specified | Uncertain significance (Oct 14, 2023) | ||
20-58991036-C-G | not specified | Uncertain significance (Jun 03, 2022) | ||
20-58991046-A-G | not specified | Uncertain significance (May 30, 2023) | ||
20-58991053-T-C | not specified | Uncertain significance (Feb 17, 2022) | ||
20-58991378-C-A | not specified | Uncertain significance (Jul 30, 2023) | ||
20-58991417-G-T | not specified | Uncertain significance (Aug 02, 2021) | ||
20-58991423-A-G | not specified | Uncertain significance (Oct 13, 2023) | ||
20-58993122-C-T | Benign (Jun 27, 2018) | |||
20-58993452-A-G | not specified | Uncertain significance (Nov 08, 2022) | ||
20-58993721-A-G | not specified | Uncertain significance (Feb 22, 2023) | ||
20-58993760-C-T | not specified | Uncertain significance (Dec 20, 2023) | ||
20-58994221-C-T | not specified | Uncertain significance (May 30, 2023) |
GnomAD
Source:
Gene | Type | Bio Type | Transcript | Coding Exons | Length |
---|---|---|---|---|---|
NELFCD | protein_coding | protein_coding | ENST00000602795 | 15 | 13926 |
pLI Probability LOF Intolerant | pRec Probability LOF Recessive | Individuals with no LOFs | Individuals with Homozygous LOFs | Individuals with Heterozygous LOFs | Defined | p |
---|---|---|---|---|---|---|
0.176 | 0.824 | 125716 | 0 | 32 | 125748 | 0.000127 |
Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible in Transcript | |
---|---|---|---|---|---|---|
Missense | 2.29 | 216 | 334 | 0.647 | 0.0000189 | 3922 |
Missense in Polyphen | 58 | 112.01 | 0.51782 | 1316 | ||
Synonymous | 0.796 | 125 | 137 | 0.913 | 0.00000860 | 1157 |
Loss of Function | 4.00 | 8 | 32.7 | 0.245 | 0.00000173 | 369 |
LoF frequencies by population
Ethnicity | Sum of pLOFs | p |
---|---|---|
African & African-American | 0.000293 | 0.000293 |
Ashkenazi Jewish | 0.00 | 0.00 |
East Asian | 0.000163 | 0.000163 |
Finnish | 0.00 | 0.00 |
European (Non-Finnish) | 0.000158 | 0.000158 |
Middle Eastern | 0.000163 | 0.000163 |
South Asian | 0.0000327 | 0.0000327 |
Other | 0.000163 | 0.000163 |
dbNSFP
Source:
- Function
- FUNCTION: Essential component of the NELF complex, a complex that negatively regulates the elongation of transcription by RNA polymerase II. The NELF complex, which acts via an association with the DSIF complex and causes transcriptional pausing, is counteracted by the P-TEFb kinase complex. The NELF complex is involved in HIV-1 latency possibly involving recruitment of PCF11 to paused RNA polymerase II. Binds RNA which may help to stabilize the NELF complex on nucleic acid. In vitro, the NELFA:NELFCD subcomplex binds to ssDNA and ssRNA in a sequence- and structure- dependent manner. {ECO:0000269|PubMed:10199401, ECO:0000269|PubMed:12612062, ECO:0000269|PubMed:27282391, ECO:0000305|PubMed:23884411}.;
- Pathway
- miR-targeted genes in epithelium - TarBase;miR-targeted genes in leukocytes - TarBase;miR-targeted genes in lymphocytes - TarBase;miR-targeted genes in muscle cell - TarBase;Initiation of transcription and translation elongation at the HIV-1 LTR;Disease;Formation of the HIV-1 Early Elongation Complex;Gene expression (Transcription);Formation of HIV-1 elongation complex containing HIV-1 Tat;Tat-mediated elongation of the HIV-1 transcript;Abortive elongation of HIV-1 transcript in the absence of Tat;HIV Transcription Elongation;HIV elongation arrest and recovery;Formation of HIV elongation complex in the absence of HIV Tat;Pausing and recovery of HIV elongation;Generic Transcription Pathway;Tat-mediated HIV elongation arrest and recovery;Pausing and recovery of Tat-mediated HIV elongation;Transcription of the HIV genome;Late Phase of HIV Life Cycle;HIV Life Cycle;HIV Infection;RNA Polymerase II Pre-transcription Events;Formation of RNA Pol II elongation complex ;RNA Polymerase II Transcription;Infectious disease;RNA Polymerase II Transcription Elongation;AndrogenReceptor;TP53 Regulates Transcription of DNA Repair Genes;Transcriptional Regulation by TP53;Formation of the Early Elongation Complex
(Consensus)
Recessive Scores
- pRec
- 0.423
Intolerance Scores
- loftool
- rvis_EVS
- -1.2
- rvis_percentile_EVS
- 5.76
Haploinsufficiency Scores
- pHI
- 0.207
- hipred
- Y
- hipred_score
- 0.704
- ghis
- 0.658
Essentials
- essential_gene_CRISPR
- E
- essential_gene_CRISPR2
- E
- essential_gene_gene_trap
- gene_indispensability_pred
- gene_indispensability_score
Gene Damage Prediction
All | Recessive | Dominant | |
---|---|---|---|
Mendelian | Medium | Medium | Medium |
Primary Immunodeficiency | Medium | Medium | Medium |
Cancer | Medium | Medium | Medium |
Mouse Genome Informatics
- Gene name
- Nelfcd
- Phenotype
Gene ontology
- Biological process
- transcription by RNA polymerase II;transcription elongation from RNA polymerase II promoter;negative regulation of transcription, DNA-templated
- Cellular component
- nucleoplasm;membrane;NELF complex
- Molecular function
- RNA binding;protein binding